Rashmi Chugh, MD
Medical Oncology · Ann Arbor, MINPI 1356427314
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Deciphera Pharmaceuticals Inc. accounts for 61.6% of it on its own, with 3 other manufacturers making up the rest.
Across 32 payments — averaging $1028.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Deciphera Pharmaceuticals Inc.$20K
- Recordati_rare_diseases_inc.$7K
- Jazz Pharmaceuticals Inc.$3K
- Ipsen Biopharmaceuticals, Inc$3K
Across 203 payments — averaging $34,283 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$4.7M
- GSK$678K
- PTC Therapeutics, Inc.$512K
- Otsuka Pharmaceutical Co., Ltd.$402K
- Trillium Therapeutics USA, LLC$210K
- Epizyme, Inc.$133K
- plus $336K from 7 others
What the payments were for
- Consulting fees$11,26034%
- Speaking & faculty fees$17,92854%
- Travel & lodging$2,5678%
- Food & beverage$1,1624%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Deciphera Pharmaceuticals Inc. | 22 | $20,267 |
| Recordati_rare_diseases_inc. | 8 | $7,269 |
| Jazz Pharmaceuticals Inc. | 1 | $2,880 |
| Ipsen Biopharmaceuticals, Inc | 1 | $2,500 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QINLOCK$17,113
- ZEPZELCA$2,880
- ONIVYDE$2,500
- VIMSELTINIB$1,988
- ROMVIMZA$600
How this compares
$32,916 in reported general payments places this provider in the 85th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GleevecImatinib Mesylate | 23 | $232,344 |
| Pazopanib Hcl | 16 | $128,853 |
| Imatinib Mesylate | 105 | $77,645 |
| XareltoRivaroxaban | 15 | $11,315 |
| Prochlorperazine Maleate | 37 | $838 |
| Olanzapine | 30 | $348 |
| Omeprazole | 11 | $342 |
| Ondansetron Hcl | 35 | $184 |
| Dexamethasone | 17 | $175 |
| Prednisone | 11 | $11 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Ann Arbor
- Harry ErbaAnn Arbor$1.1M
- Frank WeinbergAnn Arbor$195K
- Francis WordenAnn Arbor$142K
- Maha HussainAnn Arbor$114K
- Moshe TalpazAnn Arbor$83K
- Vaibhav SahaiAnn Arbor$80K
- Howard TerebeloAnn Arbor$47K
- Angel QinAnn Arbor$41K
- Erin CobainAnn Arbor$38K
- Phillip PalmbosAnn Arbor$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.